Roche Ventures, Kaiser Permanente Ventures, and Alphabet subsidiaries Verily and GV took part in a round that boosted the cancer testing platform developer's total funding to more than $237m.
US-based diagnostics technology developer Freenome completed a $160m series B round yesterday that included pharmaceutical firm Roche, internet and technology conglomerate Alphabet and care consortium Kaiser Permanente.
Investment firms RA Capital Management and Polaris Partners co-led the round, participating alongside American Cancer Society’s BrightEdge Ventures, T.Rowe Price Associates, Andreessen Horowitz, Data Collective Venture Capital and Section 32.
Roche and Kaiser Permanente took part in the round through their Roche Ventures and Kaiser Permanente Ventures vehicles respectively. Alphabet invested through both…